MINSA warns about drugs with testosterone and others

2023-02-15 15:13:32 By : Mr. Julian Pang

The Ministry of Health launched a drug alert warning about the risks in testosterone-based products, the safety profile of atypical antipsychotics and products to treat immunoglobulin, as they are associated with cerebrovascular risks.Regarding testosterone, MINSA requested that the manufacturers of products that contain testosterone as an active principle be included in the safety information in the monographs and inserts and, at the same time, communicate the risk through the drug safety notes section. from the website of the Ministry of Health.It was reported that the alert is given because some products are associated with a possible increase in the risk of heart attack and stroke.The MINSA also warned about the Zero Extreme product, which is sold on the internet under the figure of a dietary supplement specifically as a fat burner and appetite suppressant, and which does not have the authorization or permission for commercialization of the entity or of the Panamanian Food Safety Authority (AUPSA).This warning comes after learning about the case of a 21-year-old girl who presented dyspnea, palpitations, tremors and anxiety after ingesting the first dose.The United States FDA reviewed five observational studies to assess the risk of cardiovascular events associated with replacement therapy, two found cardiovascular damage, another two a significant benefit on mortality, and one study was inconclusive.Drugs containing testosterone are: Sostenon 250 mg solution for injection, Chemico Gutis 250 mg/mL oily solution for injection IM, Androgel 50 mg topical gel, Nebido 1000 mg/4mL solution for injection IM, Andriol TC 40 mg capsules.In the case of atypical antipsychotics, MINSA indicated that these are used to treat schizophrenia, bipolar disorder and depression, however the Canadian Medicines Regulatory Agency began reviewing the safety profile to evaluate information on potential risk of hepatic failure associated with antipsychotics and atypicals.Due to the above, the Department of Pharmacies and Drugs of MINSA requested that laboratories that manufacture medicines whose active ingredient is atypical antipsychotics update the monograph with this information.The drugs are: ariprpazole, asenapein, clozapine, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone.TERMS AND CONDITIONS |THE MOST BEAUTIFUL TOWNSTelemetro is a channel of MEDCOM Panama |Copyright © 2021. All rights reserved.Box 0834-00129, Panama - Republic of Panama |Address, Avenida 12 de Octubre |Telephone exchange (507) 390-6700